Selvendiran Karuppaiyah PhD

Selvendiran Karuppaiyah PhD
Asst ProfessorCollege of MedicineSelvendiran.Karuppaiyah@osumc.edu
BRT584 460 W 12th Avenue Columbus OH 43210
Phone:(614) 292-7624Fax:
  • Translational Therapeutics

Current Publications

  • Bolyard CM, Yoo JY, Wang PY, Saini U, Rath KS, Cripe TP, Zhang J, Selvendiran K, Kaur BDoxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.Clin Cancer Res in press 10/7/2014
  • Tierney BJ, McCann GA, Naidu S, Rath KS, Saini U, Wanner R, Kuppusamy P, Suarez A, Goodfellow PJ, Cohn DE, Selvendiran KAberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.Gynecol Oncol in press 7/16/2014
  • Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe TP, Parris DS, Caligiuri MA, Yu J, Old M, Kaur BBortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.Clin Cancer Res 20 3787-98 7/15/2014
  • Selvendiran K, Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DEHO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.Cancer Res 74 2316-27 4/15/2014
  • Zhao R, Han C, Eisenhauer E, Kroger J, Zhao W, Yu J, Selvendiran K, Liu X, Wani AA, Wang QEDNA damage-binding complex recruits HDAC1 to repress Bcl-2 transcription in human ovarian cancer cells.Mol Cancer Res 12 370-80 3/1/2014

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu